


G43

Cat. No.:	HY-155715
CAS No.:	690693-02-8
Molecular Formula:	C ₁₆ H ₁₁ N ₃ O ₄ S
Molecular Weight:	341.34
Target:	Bacterial; Glucosylceramide Synthase (GCS)
Pathway:	Anti-infection; Neuronal Signaling
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	G43 is a potent, selective glucosyltransferase inhibitor, with the K _d of 3.7 μM and 46.9 nM for GtfB and GtfC, respectively. G43 has antibacterial to <i>S. mutans</i> in vitro and in vivo, and can be used for dental caries study ^{[1][2]} .								
In Vitro	<p>G43 (16 h) inhibits more than 85% of <i>S. mutans</i> biofilm at 12.5 μM^[1].</p> <p>G43 (25 μM, 24 h) reduces the glucan production by the glucosyltransferase (Gtfs), and consistently inhibits the activity of both GtfB and GtfC with 80% inhibition of both enzymes^[1].</p> <p>G43 (up to 25 μM, 24 h) shows no significant difference on expression of gtfB, gtfC and gtfD in <i>S. mutans</i> UA159 cells^[1].</p> <p>G43 (50 μM, 24-48 h) reduces the biofilm formation by decreasing the production of Water-insoluble extracellular polysaccharide in wild-type <i>S. mutans</i>^[2].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>RT-PCR^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td><i>S. mutans</i> UA159 cells</td> </tr> <tr> <td>Concentration:</td> <td>3.125, 6.25, 12, 25 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>24 h</td> </tr> <tr> <td>Result:</td> <td>Showed no significant difference on expression of gtfB, gtfC and gtfD).</td> </tr> </table>	Cell Line:	<i>S. mutans</i> UA159 cells	Concentration:	3.125, 6.25, 12, 25 μM	Incubation Time:	24 h	Result:	Showed no significant difference on expression of gtfB, gtfC and gtfD).
Cell Line:	<i>S. mutans</i> UA159 cells								
Concentration:	3.125, 6.25, 12, 25 μM								
Incubation Time:	24 h								
Result:	Showed no significant difference on expression of gtfB, gtfC and gtfD).								
In Vivo	<p>G43 (100 μM twice daily for 4 weeks, topically administration) reduces <i>S. mutans</i> virulence in vivo^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>The rat model of dental caries infected with <i>S. mutans</i> UA159^[1]</td> </tr> <tr> <td>Dosage:</td> <td>100 μM twice daily for 4 weeks</td> </tr> <tr> <td>Administration:</td> <td>Topically administration</td> </tr> <tr> <td>Result:</td> <td>Reduced the buccal, sulcal, and proximal surface caries scores, but did not lose weight over the course of the study.</td> </tr> </table>	Animal Model:	The rat model of dental caries infected with <i>S. mutans</i> UA159 ^[1]	Dosage:	100 μM twice daily for 4 weeks	Administration:	Topically administration	Result:	Reduced the buccal, sulcal, and proximal surface caries scores, but did not lose weight over the course of the study.
Animal Model:	The rat model of dental caries infected with <i>S. mutans</i> UA159 ^[1]								
Dosage:	100 μM twice daily for 4 weeks								
Administration:	Topically administration								
Result:	Reduced the buccal, sulcal, and proximal surface caries scores, but did not lose weight over the course of the study.								

REFERENCES

- [1]. Zhang Q, et al. Structure-Based Discovery of Small Molecule Inhibitors of Cariogenic Virulence. *Sci Rep.* 2017;7(1):5974.
- [2]. Scaffa PMC, et al. The potential use of glycosyl-transferase inhibitors for targeted reduction of *S. mutans* biofilms in dental materials. *Sci Rep.* 2023;13(1):11889.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA